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NF-κBy an important role in early stages of HIV-1 infection and long-term persistence
of the virus. Here we determined the mechanism that regulates HIV-1 activation via prostaglandin J2 (PGJ2) in
Caco-2 cells. We showed that treatment of Caco-2 cells with PGJ2 decreased the infectivity of a luciferase
reporter virus, pHXB-luc, as well as HIV production following infection of cells with a X4-tropic virus by
antagonizing sodium butyrate, a cellular activator known to induce HIV-1 transcription. Transfection of
intestinal epithelial cells such as Caco-2, HT-29 and SW620 cells with full-length HIV-1 LTR (pLTR-luc)
revealed that PGJ2 reduced HIV-1 LTR-mediated reporter gene activity. The involvement of NF-κB in the PGJ2-
dependent down-regulation of HIV-1 transcription was further assessed using the κB-regulated luciferase-
encoding vectors. In Caco-2 cells, PGJ2 decreased IKK activity, resulting in reduced NF-κB translocation to the
nucleus. Since sodium butyrate has been associated with a chronic stress response in AIDS patients, our
results suggest that addition of PGJ2 in the environment of infected intestinal epithelial cells could reduce
HIV-1 transcription.
© 2008 Elsevier Inc. All rights reserved.IntroductionSexual transmission is the predominant mode for epidemic spread
of human immunodeﬁciency virus type-1 (HIV-1) infection world-
wide. Because semen contains both free HIV-1 virions and HIV-1-
infected cells (Bouhlal et al., 2002; Royce et al., 1997; Shepard et al.,
2000), it can lead to both free and cell-associated viral transmission.
The intestinal mucosa of the rectum, which serves as a site for virus
entry, is known to play a fundamental role in early HIV-1 infection
(Belyakov and Berzofsky, 2004; Kozlowski and Neutra, 2003; Neutra
et al., 1996). In contrast, the mechanism of HIV-1 transmission across
the epithelium is not well understood. While it is known that the
penetration of HIV-1 may occur through lesions in the epithelium
(Dickerson et al., 1996; Kozak et al., 1997), the existence of lesions is
not required (Miller et al., 1990; Spira et al., 1996). Some studies
suggest that HIV-1 can be carried to lymphocytes by dendritic cells
(Geijtenbeek et al., 2000; Pohlmann et al., 2001). It has been
proposed that HIV-1 can cross the epithelium barrier via epithelial
cell infection. Recently, a quantitative analysis of enhanced green
ﬂuorescent protein-tagged HIV infection of cells derived from the
female reproductive tract, brain and colon demonstrated that gp120-
independent HIV infection occurs in intestinal epithelial cells (Zheng
et al., 2006). These results clearly illustrate the importance of such
cells in viral latency and transmission during mucosal HIV-1 infec-umais).
l rights reserved.tion. Earlier in vitro studies showed that HIV can infect human
intestinal cell lines lacking CD4 (Fantini et al., 1991; 1993). These
studies also demonstrated that galactosylceramide (GalCer), which
binds with high-afﬁnity to gp120, can act as a CD4 surrogate HIV-1
receptor (Meng et al., 2002). In fact, Caco-2 cells, a human intestinal
cell line, can be infected by HIV-1 via GalCer and CXCR4, one of the
two known HIV chemokine coreceptors (Delezay et al., 1997; Fantini
et al., 1993). Also, primary human intestinal cells are capable of
selectively transferring R5 HIV-1 to CCR5+ cells (cells that express
both GalCer and CCR5 on their cell surface) (Meng et al., 2002). In the
study presented here, we examine whether prostaglandin J2 (PGJ2), a
lipid mediator, is able to alter HIV-1 transcription in intestinal epi-
thelial cells.
The balance of opposing prostaglandins produced in tissues pro-
foundly inﬂuences inﬂammatory responses (Harris et al., 2002). The J
series of prostaglandins, are the end product metabolites of PGD2, and
are abundantly produced by mast cells, platelets, as well as alveolar
macrophages (Ito et al., 1989; Straus and Glass, 2001). One of these
molecules, PGJ2, is a natural activator of the peroxisome proliferators-
activated receptor-γ (PPAR-γ), a nuclear receptor family member that
elicits anti-inﬂammatory activities in macrophages (Hinz et al., 2003;
Hortelano et al., 2000; Jiang et al., 1998; Ricote et al., 1998), lympho-
cytes (Clark et al., 2000; Padilla et al., 2000; Yang et al., 2000), dendritic
cells (Faveeuw et al., 2000), and endothelial cells (Imaizumi et al.,
2003). Currently, the mechanisms regulating the anti-inﬂammatory
effects of PGJ2 and other PPAR-γ agonists are poorly understood, but it
has been suggested to involve the inhibition of the nuclear factor κB
Fig. 1. PGJ2 inhibits HIV-1 transcription and viral production in a human intestinal
epithelial cell line. (A) Caco-2 cells were inoculated with standardized amounts (50 ng
of p24) of the luciferase reporter virus pHxB-luc. Caco-2 cells were pre-treated with
20 μM PGJ2 for 24 h before virus inoculation or treated with 20 μM PGJ2 in combination
with 2 mM NaBut during the virus inoculation. Then, Caco-2 cells were lysed and virus-
encoded luciferase activity was monitored. Results shown are the means (±S.D.) of four
determinations and are expressed in relative luciferase unit (RLU). These results are
representative of three independent experiments. ⁎=Pb0.05 versus cells infected with
pHxB-luc, without PGJ2 and NaBut. (B) Caco-2 cells were pre-incubated with 20 μMPGJ2
for 24 h before the addition of 2 mM NaBut alone, 20 μM PGJ2 or a combination of
NaBut-PGJ2 and virus inoculation (NL4-3). After infection, cell cultures were washed 4
times to remove unbound viruses. Virus production was assessed by measuring p24
level after 72 h. Viral infections were performed in quadruplicate for each treatment.
⁎=Pb0.000 for Caco-2 cells infected with NL4-3 and treated with NaBut plus PGJ2
compared to infected cells treated or not treated with NaBut.
2 M. Boisvert et al. / Virology 380 (2008) 1–11(NF-κB) signaling pathway (Daynes and Jones, 2002; Rossi et al., 2000).
PPAR-γ is also expressed at high levels both in the colonic epithelium
and intestinal epithelial cells (Fajas et al., 1997; Lefebvre et al., 1998;
Saez et al., 1998; 2004; Sarraf et al., 1998), where, depending on the
model systemstudied, it can result in either an increase or a decrease in
proliferation (Brockman et al., 1998; Lefebvre et al., 1998).
The expression of HIV-1 genes in infected cells is dependent on the
interaction of host cellular transcription factors with cis-regulatory
elements within the viral long terminal repeat (LTR). The transcription
factor NF-κB is known to play a central role in the activation of HIV-1
gene expression. The enhancer in the U3 region of LTR contains two
NF-κB binding sites (Siebenlist et al., 1994) that are critical for LTR
promoter activity and important for optimal HIV-1 replication
(Santoro et al., 2003; Siebenlist et al., 1994). Sodium butyrate, a fer-
mented product of intestinal bacteria of undigested carbohydrates and
dietary ﬁbers, has been shown tomarkedly induce HIV-1 transcription
via NF-κB (Quivy et al., 2002). AIDS patients with weight loss possess a
signiﬁcant concentration of urinary butyrate that has been linked to a
chronic metabolic stress weakening progressively the host defenses
(Stein et al., 1997).
In the study presented here, we examined the possible antiviral
activity of PGJ2 against HIV-1 in intestinal epithelial cells, one of the
possible routes of HIV-1 viral entry. We demonstrate that PGJ2 inhibits
HIV-1 transcription in Caco-2 cells and modulates the NF-κB
transcription factor. This PGJ2-mediated inhibition of NF-κB is
associated with reduced IKK activity and, therefore, reduced nuclear
translocation of NF-κB. A greater understanding of the early interac-
tion between HIV-1 and mucosa will aid in the development of
therapies that prevent HIV-1 transmission through mucosal surfaces,
thereby controlling the spread of the virus.
Results
Treatment of Caco-2 cells with PGJ2 inhibits HIV-1 transcription and
viral production
Because the effect of PGJ2 on HIV-1 transcription in intestinal
epithelial cells has never been reported, we initially tested whether
this potent anti-inﬂammatory molecule could modulate HIV-1
replication and particle production in Caco-2 cells, a human intestinal
cell line that mimics rectal epithelium. The cells were treated with
either PGJ2 alone for 24h before the addition of sodium butyrate
(NaBut) and the virus or with PGJ2, NaBut and the virus. Standardized
amounts (50ng of p24) of the luciferase reporter virus pHxB-luc, a
replication-competent T-tropic strain originally derived from pHxB-
2D (Chen et al., 1994) were used to inoculate Caco-2 cells. In our
experiments, sodium butyrate was chosen as a positive control for
three reasons: First, butyrate, a short chain fatty acid produced by
bacterial fermentation in the colon, is a primary source of energy for
intestinal epithelial cells (Singh et al., 1997). Second, AIDS patients
with loss show a high level of urinary butyrate (Stein et al., 1997) and
third, NaBut is a deacetylase inhibitor that has been shown to activate
HIV-1 replication in cells of T-lymphoid andmonocytoid origin (Golub
et al., 1991). Forty-eight hours post-inoculation, the cells were lysed,
and virus-encoded luciferase activity was monitored using a lumin-
ometer. The results depicted in Fig. 1B indicate that HIV-1 infection in
absence of any treatment results in low virus production. In contrast,
treatment with NaBut alone results in more efﬁcient pHxB-luc
replication and elevated levels of virus production as compared to
control cells. Interestingly, when the Caco-2 cells were pre-treated or
treated with 15d-PGJ2 (20μM), the NaBut-induced increase in
replication and viral production was completely abrogated. We also
determined whether PGJ2 treatment of NaBut-treated Caco-2 cells
could affect HIV-1 viral protein generation in cells infected with wild-
type NL4-3, a X4-tropic virus. Expression of HIV-1 was assessed by
p24 core antigen production, by use of an ELISA. In Fig. 1B, we showedthat addition of NaBut in infected-Caco-2 cells increased HIV
expression while the combination of NaBut and PGJ2 signiﬁcantly
decreased p24 production (p = 0.000). In contrast, PGJ2 alone did not
affect p24 production compared to untreated infected cells.
Next, we examined the effects of PGJ2 on HIV-1 promoter activity
in intestinal epithelial cells. We transiently transfected Caco-2 cells
with a construct (pLTR-luc) that contains the full-length HIV-1 LTR
driving the expression of the luciferase gene. The transfections were
performed in the presence of increasing concentrations of PGJ2 (5 to
30 μM) and NaBut for 24h. As shown in Fig. 2A, we observed a 13-fold
increase in luciferase activity in cells transfected with the full-length
HIV-1 LTR in the presence of 2 mM of NaBut in Caco-2 cells. In
contrast, treatment with PGJ2 alone had no effect on luciferase activity
(data not shown). Interestingly, when the pLTR-luc-transfected Caco-2
cells were treatedwith increasing concentrations of PGJ2, we observed
a dose-dependent suppression in the NaBut-induced luciferase
Fig. 2. Dose-dependent and kinetic analyses of PGJ2-mediated negative effect on HIV-1 LTR activity. Caco-2 cells were transiently transfected with pLTR-luc and (A) treated with
increasing concentrations of PGJ2 (5, 10, 15, 20, 25 and 30 μM) used in combinationwith 2mMNaBut in a 24 h incubation period and (B) stimulated or not stimulated with 20 μMPGJ2
in combinationwith 2 mMNaBut for different time periods (8, and 24 h) prior to monitoring luciferase activity in cell lysates. (C) SW620 and HT-29 were transiently transfected with
pLTR-luc and treated with 20 μM PGJ2 alone or in combination with 2 mM NaBut for 24 h prior luciferase assays. Results shown are the means (±S.D.) of four determinations and are
expressed in relative luciferase unit (RLU). These results are representative of three independent experiments.
Fig. 3. PGJ2 slightly decreased the cell viability in a concentration-dependent manner.
Caco-2 cells were stimulated with increasing concentration of PGJ2 (1, 5, 10, 20 and
30 μM) in combination with 2 mM NaBut for 24 h and cell viability was estimated using
a Trypan blue exclusion assay. The data shown are from one out of three representative
experiments.
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respectively). Next, we performed an experiment to determine the
time required for the optimal HIV-1 LTR suppression mediated by
PGJ2. As shown in Fig. 2B, the maximal PGJ2-mediated inhibition was
detected 24h post-treatment, a time that coincides with the optimal
activation of luciferase activity induced by NaBut treatment (29.2-fold
at 24h). It should be noted that, in Figs. 2A and B, the basal level of
luciferase activity in the control cells is elevated. Caco-2 cells have
been shown to exhibit constitutively elevated NF-κB activity (Voboril
and Weberova-Voborilova, 2006) and this is likely the cause of the
elevated basal HIV-1 activity in our experiments. Furthermore, this
initial activation in Caco-2 cells may also explain why PGJ2 induces an
inhibitory effect even in control cells. To exclude the fact that PGJ2
repression of HIV-1 LTR is cell-type speciﬁc, we transiently transfected
two other human colonic adenocarcinoma cell lines, SW620 and HT-
29 with pLTR-luc (Fig. 2C). In these cell lines, PGJ2 has a strong
repressive effect on the luciferase activity on NaBut-stimulated cells.
Our results clearly demonstrate that PGJ2 inhibition of NaBut-induced
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intestinal epithelial cell lines such as HT-29 and SW620.
To investigate the effect(s) of PGJ2 on cell viability, Caco-2 cells
were exposed to varying concentrations of PGJ2 for 24h. Cell viability
then was estimated using a Trypan blue exclusion assay. In Fig. 3, we
noted that PGJ2 treatment induces a dose-dependent, slight decrease
in cell viability. MTT and DNA fragmentation assays were also per-
formed to further examine the effect(s) of PGJ2 on cell viability and
apoptosis. The results demonstrated that the suppressive effect of PGJ2
was not mediated by the inhibition of Caco-2 viability or by the
induction of apoptosis (data not shown).
Prostaglandin D2 has been shown to promote cell cycle arrest in
G0/G1 in leukemia cells (Fukushima et al., 1982a; 1982b). To
determine whether such effect on cell cycle may be responsible for
the observed inhibition of NaBut-induced HIV-1 LTR by PGJ2 in Caco-2
cells, we performed cell cycle analysis. Results from a representative
experiment using ﬂow cytometry of propidium iodide-stained Caco-2
cells are shown in Fig. 4. We found that 20 μM PGJ2 did not change the
cell cycle distribution compared to the control. In untreated cells and
PGJ2-treated cells, we observed a similar percentage of cells in G1
phase (57.4% and 56.0%, respectively). Similar results were also
obtained in HT-29 (Fig. 4). Taken together, these data indicate that
PGJ2, without signiﬁcantly changing cell viability or the cell cycle by
blocking them in G1 phase or altering apoptosis, profoundly affects
HIV-1 replication and gene expression in a well-established intestinal
epithelial cell line, Caco-2 cells.
PGJ2 inhibition of HIV-1 transcription is mediated by a
PPAR-γ-independent mechanism
It has been shown previously that PGJ2 exerts its effect(s) on cells
by activating the PPAR-γ transcription factor via PPAR-γ, the natural
ligand of PGJ2 (Schoonjans et al., 1996; Spiegelman, 1998). However,
several studies have reported PPAR-γ independent effects of PGJ2 on
transcriptional regulation via the modulation of NF-κB (Rossi et al.,
2000; Straus et al., 2000). We next wanted to determine whether
PPAR-γ was a key player in the above-described down-regulation of
HIV-1 LTR gene expression mediated by PGJ2. First, we examined
whether PGJ2 and/or NaBut treatment had an effect on the expression
of PPAR-γ using RT-PCR with PPAR-γ-speciﬁc primers (Kato et al.,
2004) to analyze the PPAR-γ mRNA levels in untreated, PGJ2-treated,
PHA/PMA-treated or NaBut-treated Caco-2 cells. The basal levels of
PPAR-γ mRNA in Caco-2 cells was similar to that observed by othersFig. 4. Effect of PGJ2 on Caco-2 and HT-29 cells cell cycle progression. Cells were exposed
to 20 μM PGJ2 for 24 h. The percentage of cells in G1, S and G2/M was measured by ﬂow
cytometry after propidium staining. The data shown are from 1 out of 3 representative
experiments.previously (Lefebvre et al., 1999; Wachtershauser et al., 2000) and
PHA/PMA treatment was chosen here as a positive control. Interest-
ingly, neither PGJ2 nor NaBut altered PPAR-γ mRNA levels in Caco-2
(Fig. 5A). The results represented in Fig. 5A represent a typical
experiment that was repeated three times with cells of different
passage numbers.
To determine whether the inhibitory effect of PGJ2 is PPAR-γ-
dependent, we examined the effect(s) of ciglitazone, a PPAR-γ agonist,
on PGJ2-mediated HIV-1 promoter inhibition. For this experiment,
Caco-2 cells were transiently transfected with the pLTR-luc reporter
construct and eithermock-treated or treatedwith NaBut alone, ciglita-
zone alone, or NaBut plus ciglitazone. The treatment of the cells with
NaBut alone induced a 11.7-fold increase in luciferase gene expression
(Fig. 5B) while cells treated with ciglitazone slightly increase in
luciferase gene expression compared to the control. When cells are
treated with a combination of ciglitazone and NaBut, we did not
observe the inhibition of HIV-1 promoter activity seenwith PGJ2. Since
ciglitazone is unable to mimic the PGJ2-mediated decrease in HIV-1
LTR transcription, these results suggest that PGJ2 represses HIV-1 LTR
in a PPAR-γ-independent manner. To conﬁrm that PGJ2 represses LTR
activity by a mechanism independent of PPAR-γ, we blocked PPAR-γ
receptor activation by using a speciﬁc human PPAR-γ antagonist
(GW9662). PPAR-γ antagonist GW9662 did not alter the inhibitory
effects of PGJ2 on NaBut-induced LTR activity (Fig. 5B).
PPAR-γ is a ligand activated nuclear receptor, which binds as
heterodimers (PPAR-γ /RXR) to speciﬁc DNA sequences called PPAR
response elements (PPRE) to regulate gene expression. To conﬁrm that
PGJ2-mediated repression on HIV-1 LTR is PPAR-γ-independent, we
performed EMSA to examine whether the addition of PGJ2 will modify
the binding of PPAR-γ to its corresponding sequence. In HIV-1 LTR,
PPAR-γ binds to the sequence called the nuclear receptor-responsive
element (NRRE) (Ladias, 1994). Incubation of the nuclear proteins
obtained from treated-Caco-2 cells with the labeled NRRE oligonu-
cleotide resulted in the formation of a retarded complex (Fig. 5C).
Caco-2 cells express PPAR-γ at basal level (Allred and Kilgore, 2005)
that binds to its speciﬁc sequence in the HIV-1 LTR. Cells treated with
PGJ2 alone, NaBut alone, or with NaBut and PGJ2 did not modulate the
level of PPAR-γ that binds to the NRRE. The binding speciﬁcity of
PPAR-γ to the NRRE oligonucleotidewas demonstrated by a supershift
experiments with an anti-PPAR-γ antibody (data not shown). These
results indicate that PPAR-γ is not directly involved in the inhibition of
NaBut-induced LTR activity by PGJ2. Moreover, the activation of HIV-1
LTR activity by NaBut is not mediated via PPAR-γ.
The PGJ2-mediated inhibition of HIV-1 LTR activation in Caco-2 cells
requires NF-κB binding sites
The PPAR-γ-independent mechanism by which PGJ2 mediates its
anti-inﬂammatory effect can be dependent upon the inhibition of the
NF-κB signaling pathway (Daynes and Jones, 2002; Li, Pascual, and
Glass, 2000; Rossi et al., 2000). The NF-κB binding sites within the
HIV-1 promoter confer a high level of viral transcription in many cell
types (Rabson and Lin, 2000). To investigate the functional role of NF-
κB in the PGJ2-mediated suppression of NaBut-induced HIV-1 LTR
activation, Caco-2 cells were transiently transfected with pκB-TATA-
luc or pNFκB-luc expression plasmids. The cells were then treated
with NaBut alone or in combination with increasing concentrations
of PGJ2 and assayed for luciferase activity. The results demonstrated
that the NaBut-induced luciferase activity of the pκB-TATA-luc
construct, which contains the HIV-1 enhancer, is abrogated by PGJ2
in a dose-dependent manner (Fig. 6A). A control construct containing
the HIV-1 enhancer with inactivated NF-κB binding sites, pmκB-luc,
was used to show that NF-κB is necessary for the NaBut activation of
the HIV-1 LTR in Caco-2 (Fig. 6A). Similar results to pκB-TATA-luc
were found using the pNFκB-luc construct, which contains ﬁve
consensus NF-κB binding sites (Fig. 6B). Together, these data suggest
Fig. 5. PGJ2 inhibition of HIV-1 transcription is mediated by a PPAR-γ-independentmechanism. (A) Caco-2 cells were treatedwith 20 μMPGJ2 in combination or notwith 2mMNaBut.
The effect of these activators on PPAR-γ mRNA expression was determined by RT-PCR. The data shown are from 1 out of 3 representative experiments. (B) Caco-2 cells were
transiently transfected with pLTR-luc and cells were either mock-treated or not with 20 μM PGJ2 alone, ciglitazone alone (1, 5, and 10 μM), 10 μM GW9662 with or without 2 mM
NaBut for 24 h. Then, Caco-2 cells were lysed and luciferase activity was monitored. Results shown are the means (±S.D.) of four determinations and are expressed in relative
luciferase unit (RLU). These results are representative of three independent experiments. (C) Caco-2 cells were either left untreated or were incubated for 15 min with 20 μM PGJ2
with or without 2 mMNaBut. The nuclear extracts were next incubated with a 32P-end-labeled synthetic double-stranded NNRE probe and supershift experiments were achieved by
using the anti-PPAR-γ antibody (Santa Cruz).
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activation in Caco-2 cells.
PGJ2 inhibits IκBα phosphorylation by IκB kinase (IKK) and the nuclear
translocation of NF-κB
To better characterize themechanism(s) bywhich PGJ2 inhibits the
activity of NF-κB, we examined the effects of PGJ2 on IκB kinase
activity and the nuclear translocation of NF-κB. First, to determine
whether PGJ2 could alter the stability of IκBα proteins thereby altering
NF-κB activation, we performed an IKK kinase assay using extracts
from Caco-2 cells treated with PGJ2. The results, depicted in Fig. 7A,
demonstrate that IKK activity is stimulated in the presence of NaBut
but inhibited in PGJ2 and NaBut-treated cells. A Western blot analysis
of IκBα conﬁrmed that the variations in the intensity of the band are
not due to a difference in gel loading but rather a modiﬁcation in the
kinase activity of IKK in Caco-2 cells. Next, nuclear protein extracts
from Caco-2 cells treated for 15min were subjected to mobility shiftassays using NF-κB binding site-speciﬁc probes. Greater NF-κB-
binding activity was detected in NaBut-treated Caco-2 cells than in
untreated cells (Fig. 7B). The nature of the NF-κB binding was
comparable to that seen in cells treated with TNF-α, but the binding
was slightly stronger in NaBut-treated cells as compared to the
positive control. Little increase in NF-κB binding was detected in
nuclear extracts from PGJ2-NaBut-treated cells. The speciﬁcity of the
signal was shown by competition experiments using a 50-fold excess
of the unlabeled oligonucleotide. Supershift analysis demonstrated
that the binding of the p65 subunit of NF-κB was affected by PGJ2
treatment of Caco-2 cells while the binding of the p50 subunit was
unaffected (data not shown). Together, these data indicate that, in
Caco-2 cells, PGJ2 represses the ubiquitous transcription factor NF-κB,
which results in the repression of HIV-1 transcription.
Cyclopentone prostaglandin, such has PGA1, has been shown to
enhance the expression of IκBα, a primary inhibitor of the pro-
inﬂammatory transcription factor NF-κB (Thomas et al., 1998). We
next examined whether PGJ2 can also increases IκBα gene expression
Fig. 6. NF-κB-dependent inhibition of HIV-1 LTR by PGJ2. Caco-2 cells were transiently
transfected with (A) pκB-TATA-luc, pmκB-luc and (B) pNF-κB-luc. Then, cells were
treated with increasing concentrations of PGJ2 (5, 10, 15, 20, 25 and 30 μM) used in
combination with 2 mM NaBut in a 24 h incubation period. Caco-2 cells were lysed and
luciferase activity was monitored. Results shown are the means (±S.D.) of four
determinations and are expressed in relative luciferase unit (RLU). These results are
representative of three independent experiments.
Fig. 7. PGJ2 inhibits IκBα phosphorylation by IκB kinase (IKK) and nuclear translocation
of NF-κB. (A) Kinase assay was performed on Caco-2 treated with PGJ2 (20 μM) and
NaBut (2 mM) as described in Materials and methods. The data shown are from one out
of three representative experiments. The bands were quantitated by densitometric
scanning (B) Caco-2 cells were either left untreated or were incubated for 15 min with
either PGJ2 (20 μM) and NaBut (2 mM) or 2 ng /ml TNF-α (positive control). The nuclear
extracts were next incubated with a 32P-end-labeled synthetic double-stranded NF-κB
probe and competition experiments were achieved by using 50-fold excess of cold NF-
κB probe The position of the speciﬁc complex bound by the kappa B site probe is
indicated by an arrow on the left side.
Fig. 8. PGJ2 failed to induce change in IκB-α transcription. Caco-2 cells were treated
with 20 μMPGJ2 in combinationwith 2mMNaBut. The effect of these activators on IκBα
mRNA expressionwas determined by RT-PCR. The data shown are from one out of three
representative experiments.
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alone, PGJ2 alone, or NaBut and PGJ2. We then performed RT-PCR using
IκBα-speciﬁc oligos (Bottero et al., 2001). Treatment of Caco-2 cells
with PGJ2 did not induce IκBα transcriptionwhile Caco-2 cells treated
for 15min with 2 ng/ml TNF-α enhanced IκBα transcription (2.3-fold,
data not shown). Together, these experiments demonstrate that, in
Caco-2 cells, the cyclopentone PGJ2 can inhibit NaBut-induced NF-κB
binding activity, and this effect is caused by a reduction in the activity
of IKK which results in reduced NF-κB nuclear translocation but not
alterations in IκBα gene expression.
Discussion
During the sexual transmission of HIV-1, mucosal surfaces re-
present a major route through which the virus is transmitted.
However, the mechanisms by which HIV-1 virions can cross the
epithelium remain unclear. Despite controversies (Asin et al., 2004;
Chenine et al., 1998; Collins et al., 2000; Harouse et al., 1998a; 1998b;
Hu et al., 2000; Zheng et al., 2006), a recent study reported that CD4-
cells, especially cells derived from the female reproductive tract, brain,
and colon, are capable of being infected by HIV-1 in a gp120-
independentmanner (Zheng et al., 2006). Theyperformedquantitative
analysis using a direct and sensitive approach with EGFP-modiﬁed
viral strains to demonstrate that epithelial cell lines, like Caco-2 cells,
from the gastro-intestinal tract can be infected by HIV-1. More
importantly, they found that the viruses generated by the infected
epithelial cells were highly infectious. Thus, they proposed that
infection of epithelial cells might facilitate HIV-1 penetration into
the epithelium barrier (Zheng et al., 2006). Following viral replication
in the infected epithelial cells, newly formed HIV virions may be
discharged into the basolateral side of the epithelium and exposed toimmune cells present in the mucosal milieu. This process may ulti-
mately lead to the dissemination of the virus throughout the body.
Therefore, it is essential to understand the mechanisms by which HIV
7M. Boisvert et al. / Virology 380 (2008) 1–11replication in epithelial cells can be modulated by the immune system
molecules present in themucosalmilieu. Prostaglandins play key roles
in inﬂammation. During the time course of inﬂammation, the pros-
taglandins proﬁle shifts from the predominantly pro-inﬂammatory
PGE2 to the anti-inﬂammatory PGJ2, which is the end product meta-
bolite of PGD2 (Gilroy et al., 1999; Ianaro et al., 2001; Kapoor et al.,
2005a, 2005b). Pro-inﬂammatory molecules such as PGE2 are up-
regulated duringHIV-1 infection (Grifﬁn et al., 1994; Ramis et al.,1991)
leading to an imbalance in PGJ2 production. Given that the cyclopen-
tone prostaglandin PGJ2 has potent anti-inﬂammatory properties, we
examined whether the addition of PGJ2 could inhibit HIV-1 transcrip-
tion in intestinal epithelial cells. This study demonstrates for the ﬁrst
time that PGJ2 can repress NF-κB-dependent HIV-1 transcription in
Caco-2 cells, an established epithelial cell line that is able to be infected
by HIV-1 (Delezay et al., 1997; Fantini et al., 1992; 1993; Zheng et al.,
2006).
Cyclopentone prostaglandins such as PGA1 possess potent antiviral
activity against awide variety of viruses such as herpesviruses (Hughes-
Fulford et al., 1992; Yamamoto et al., 1987), poxviruses (Santoro et al.,
1982), paramyxoviruses (Amici et al., 1992; Santoro et al., 1980),
orthomyxoviruses (Santoro et al., 1988), picornaviruses (Ankel et al.,
1985), togaviruses (Mastromarino et al., 1993), rhabdoviruses (Ankel,
Mittnacht, and Jacobsen, 1985; Santoro et al., 1983) and retroviruses
(Hayes et al., 2002; Rozera et al., 1996; Skolnik et al., 2002). In macro-
phages, rosiglitazone, troglitazone, and PGJ2 as well as fenoﬁbrate (a
PPAR-α agonist) can inhibit HIV-1 replication in U1 cells (Skolnik et al.,
2002), while PGA1 and PGA2 can inhibit HIV-1 replication in U937 cells
and humanmonocyte-derivedmacrophages (Hayes et al., 2002). During
acute HIV-1 infection in the well-characterized T cell line CEM-SS,
treatment with cyclopentone prostaglandins such as PGA1 and PGJ2
profoundly alters viral replication (Rozera et al., 1996). Moreover, this
antiviral effect does not seem to be mediated by alterations in the
expression of α-, β-, or γ-interferon, TNF-α, TNF-β, IL-6 or IL-10 in HIV-
infected CEM-SS but rather by a direct, as yet unidentiﬁed, mechanism
(Rozera et al., 1996). In the study presented here, we demonstrate that
PGJ2 strongly suppresses HIV-1 replication and expression in Caco-2
cells infectedwith a X4-tropic virus, NL4-3, aswell as HIV LTR activation
in Caco-2, SW620 and HT-29 (Figs. 1 and 2).
Sodium butyrate plays major roles in HIV infection. Indeed,
urinary butyrate levels were increased in the AIDS patients with
weight loss (2.83±0.67 μmol/l) relative to the controls (1.31±
0.13 μmol/l, Pb0.05), with the HIV+ patients (1.65±0.18 μmol/l) and
AIDS patients without weight loss (1.90±0.22 μmol/l) falling in
between (Stein et al., 1997). The data are consistent with a low, but
chronic rate of bacteria and/or bacterial products seeping across a
compromised colonic wall causing a chronic low stress response in
AIDS patients. Moreover, NaBut is a deacetylase inhibitor that has
been shown to activate HIV-1 replication in cells of T-lymphoid and
monocytoid origin (Golub et al., 1991). Our results indicate that PGJ2
pre-treatment (prophylactic) or co-treatment of NaBut-treated cells
signiﬁcantly reduces HIV replication. Using a pLTR-luc reporter
plasmid (Fig. 2), we determined that the PGJ2-mediated suppression
of HIV-1 replication is a result of the inhibition of promoter activity.
This effect is dose-dependent (Fig. 2A), a ﬁnding that suggests the
activity is speciﬁc. Using Trypan blue exclusion, MTT and DNA frag-
mentation assays, we determined that PGJ2 treatment does not affect
cell survival (Fig. 3). These results are consistent with previous
reports showing that PGJ2 effects the cell survival of epithelial cells at
doses of PGJ2 greater than 30 μM and exposure time of at least 30 h
(Shimada et al., 2002). Treatment of leukemia cells with PGD2, leads
to cell cycle arrest in G1 (Fukushima et al., 1982a; 1982b). In our
model, intestinal epithelial cell lines treated with PGJ2 do not change
their cell cycle distribution (Fig. 4). Thus, cell cycle arrest in G1 phase
is not responsible for the inhibition of HIV-1 LTR activation by PGJ2.
We next examined whether PGJ2 exerts its inhibitory activity in a
PPAR-γ-dependent manner. We found that ciglitazone failed to mimicthe PGJ2-induced suppression of LTR activity (Fig. 5), a result that
suggests a PPAR-γ-independent mechanism, such as the NF-κB
pathway, may play a role in this effect in intestinal epithelial cells.
This result is in contrast to those of Skolnik et al. in 2002 (Skolnik et al.,
2002) that showed that ciglitazone was able to reduce the HIV-1
promoter activity in monocytes and in peripheral blood mononuclear
cells (PBMCs). Surprisingly, the treatment of NaBut-stimulated Caco-2
cells with ciglitazone induced luciferase activity in an additive
manner. The induction of NF-κB activity in colon cancer cells via p65
phosphorylation has been previously reported (Chen and Harrison,
2005), and this phenomenon may explain why we observed an
increase in luciferase expression following the ciglitazone treatment
of NaBut-treated Caco-2 cells. When we blocked the PPAR-γ receptor
with a speciﬁc PPAR-γ antagonist, GW9662, we failed to interfere with
the inhibition of HIV LTR activity by PGJ2 (Fig. 5B). Similarly,
expression of IL-1β in human chondrocytes is inhibited by PGJ2 by a
PPAR-γ-independent mechanism (Boyault et al., 2001) as well as IL-8
expression in endothelial cells (Jozkowicz et al., 2001). As demon-
strated with EMSA performed with the oligonucleotide corresponding
to the binding sequence of PPAR-γ in the HIV-1 LTR, addition of PGJ2
alone, NaBut alone or NaBut and PGJ2 did not modify the basal level of
PPAR-γ observed in Caco-2 cells (Fig. 5C). Together, these data suggest
that the PGJ2 regulation of HIV-1 transcription is mediated by a PPAR-
γ-independent mechanism.
Finally, we examined the role of the NF-κB pathway in the PGJ2-
mediated repression of the HIV-1 LTR since PGJ2 have been shown to
profoundly reduce the binding activity of NF-κB (Daynes and Jones,
2002; Rossi et al., 2000). Using reporter plasmids, we found that NF-
κB activity is repressed in PGJ2-treated Caco-2 cells (Fig. 6A) and that
PGJ2 potently inhibits NF-κB-dependent HIV-1 transcription (Fig. 6B)
in a PPAR-γ-independent manner. Although previous studies have
shown that cyclopentone prostaglandins signiﬁcantly alter HIV-1
replication in T cells andmonocytes/macrophages, this is the ﬁrst time
that NF-κB has been shown to mediate such an inhibitory effect. The
ability of PGJ2 to modulate NF-κB activity could explain the NF-κB-
dependent effect on HIV-1 transcription that has been reported pre-
viously (Hayes et al., 2002; Rozera et al., 1996; Skolnik et al., 2002). We
speciﬁcally examined these effects in Caco-2 cells, an epithelial cell
line and we found that IKK activity was lower in Caco-2 cells treated
with PGJ2 and that the inhibition of IKK activity was direct (Fig. 7)
without increasing IκBα mRNA expression (Fig. 8). Another group
(Scher and Pillinger, 2005) reported an inhibitory effect of PGJ2 on NF-
κB activation and expression of pro-inﬂammatory genes such as COX-
2, IL-1β and TNF-α. Interestingly in human chondrocytes, 15d-PGJ2,
but not troglitazone, modulates IL-1β expression by inhibiting NF-κB
and AP-1 activation pathways, a mechanism independent of PPAR-γ as
observed with PGJ2 and NaBut-induced LTR activation.
In conclusion, the present work describes the potentiality of the
anti-inﬂammatory molecule, PGJ2, to modulate the NaBut effect on
HIV-1 LTR in intestinal epithelial cells by a PPAR-γ-independent
mechanism via the inhibition of NF-κB translocation to the nucleus.
Our results suggest that such prostaglandins may have therapeutic
value in the treatment of HIV-1 infected individuals where inhibition
of NF-κB activity may be required.
Materials and methods
Reagents
PGJ2, phorbol 12-myristate 13-acetate (PMA), phytohemagglutinin
(PHA), tumor necrosis factor-α (TNF-α) and sodium butyrate (NaBut)
were purchased from Sigma (St-Louis, MO). A stock solution of PGJ2
(3.16 mM) was prepared by dissolving the lyophilized product into
absolute ethanol and was stored at −20 °C until needed. Sodium
butyrate was prepared in water at a concentration of 2.27 M and was
stored at −20 °C until needed. Fugen-6 for transient transfections was
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purchased from Biomol (Plymouth Meeting, PA).
Cells and culture conditions
The human colonic adenocarcinoma cell line Caco-2 (HTB37) from
the American Type Culture Collection ((ATCC) Manassas, VA, USA) was
grown in Minimum Essential Medium Eagle (Sigma) supplemented
with 20% heat-inactivated fetal bovine serum (Wisent, St-Bruno, Qc),
sodium pyruvate 0.5 mM (Sigma), penicillin–streptomycin (Wisent),
and non-essential amino acids (Sigma). The SW620 cell line (ATCC)
was grown in RPMI 1640 supplemented with 10% heat-inactivated
fetal bovine serum (Wisent), penicillin–streptomycin (Wisent), and
non-essential amino acids (Sigma). The human colonic adenocarci-
noma cell line HT-29 (ATCC) was grown in DMEM (Sigma) supple-
mented with 10% heat-inactivated fetal bovine serum (Wisent, St-
Bruno, Qc), sodium pyruvate 0.5 mM (Sigma), penicillin–streptomycin
(Wisent), and non-essential amino acids (Sigma). The cell lines were
grown at 37 °C in a 5% atmosphere.
Plasmids
The pLTR-luc plasmid contains the luciferase reporter gene under
the control of wild-type (GGGACTTTCC) HIV-1HXB2 LTR (−453 to +80)
while pmκB-luc has mutated NF-κB sites (CTCACTTTCC) (Henderson
et al., 1995) and were generously provided by Dr. K. Calame (Columbia
University, NY). The commercial pNFB-luc molecular construct
contains ﬁve consensus NF-κB-binding sequences placed in front of
the luciferase gene along with a minimal promoter (Stratagene, La
Jolla, CA). The pκB-TATA-luc plasmid contains the HIV-1 enhancer
region (−105/−70) and a TATA box placed upstream of the luciferase
gene (Sun et al., 1996). This plasmid is a generous gift from Dr. W. C.
Greene (The J. Gladstone Institutes, San Francisco, CA). The proviral
plasmid pHXB-lucwas originally derived frompHXB-2D, fromwhich a
part of the nef gene was deleted and replaced with the reporter luci-
ferase gene (Chen et al., 1994). This infectious molecular clone of HIV-1
was kindly provided by Dr. D. Baltimore (Massachusetts Institute of
Technology, Cambridge, Mass.).
Reverse transcription-polymerase chain reaction (RT-PCR). Total
cellular RNA was extracted from Caco-2 by the Trizol method
following the manufacturer recommended protocol (Invitrogen,
Burlington, ON). First-strand synthesis from total RNA was performed
with Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV)
reverse transcriptase (Promega, Madison, WI) with an oligo-d(T)
primer as described by the manufacturer. Five hundred ng of each
samples was subjected to semi-quantitative PCR for 25 cycles at 95 °C
for 0.5 min, 60.0 °C for 1 min, 72 °C for 1 min for 25 cycles and a ﬁnal
extension at 72 °C for 5 min with the speciﬁc primers for PPAR-γ. A
combination of a forward primer, 5′-GAGATCACAGAGTATGCCAA-3′,
and a reverse primer, 5′-CTGTCATCTAATTCCAGTGC-3′, was used for
detection of PPAR-γ cDNA (Kato et al., 2004). PCR ampliﬁcation of IκB-
α was performed using the forward primer, 5′-GCTGAAGAAG-
GAGCGGCTACT-3′, and the reverse primer, 5′-TCGTACTCCTCGTCTTT-
CATGGA-3′ (Bottero et al., 2003). A combination of a forward primer,
5′-CCATCACCATCTTCCAGGAG-3′, and a reverse primer, 5′-GCATG-
GACTGTGGTCATGAG-3′, were used for glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) cDNA as an internal control. Preliminary
experiments were performed to ensure the linearity of the PCRs.
Transient transfections and cell stimulations
Transient transfections of Caco-2 cells were carried out using as
described by themanufacturer. Three μg of plasmids (pNF-κB-luc, pκB-
tata-luc and pLTR-luc) were mixed with Fugen-6 in a 3:1 ratio and
incubated 15 minwith 1×106 cells. One hundred μl of transfected cells
were plated in 96-wells and were allowed to rest overnight in free FBSmedium before treatment with 1 to 30 μM PGJ2 or 1 to 10 μM ciglita-
zone or 10 μM GW9662 in combination or not with 2 mM sodium
butyrate. Following the 24h incubationperiod, 25 μl of cell culture lysis
buffer (25 mM Tris phosphate, pH 7.8, 2 mM dithiothreitol (DTT), 1%
Triton X-100, and 10% glycerol) were added before incubation at room
temperature for 30 min on vortex. An aliquot of cell extract (50 μl) was
mixed with 100 μl of luciferase assay buffer (20 mM Tricine, 1.07 mM
(MgCO3)4Mg(OH)25 H2O, 2.67 mM MgSO4, 0.1 mM EDTA, 270 μM
coenzyme A, 470 μM luciferin, 530 μMATP, and 33.3mMDTT), and cell
lysateswere evaluated for luciferase activity by Lumat LB9507Berthold
luminometer (Mander Scientiﬁc Company Inc. Guelph, ON). Light
output was measured for 20 s with a two seconds delay. Values are
expressed as RLU (Relative Light Unit) as measured by the apparatus.
Measurement of cell viability
Cell viability was determined by the Trypan blue exclusion assay.
The cells were harvested using 0.025% trypsin, incubated in solution
with 4% Trypan blue, and were counted by a hemacytometer under
the light microscope. Cells failing to exclude the dye were considered
nonviable.
MTT assays
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium
bromide) assaywas used tomeasure the viability of cells bymeasuring
the activity of dehydrogenases (Mosmann, 1983). Brieﬂy, stimulated
Caco-2 cells were seeded at 1×105 cells per well of a 12 well-plate
and allowed to attach overnight. Cell growth medium was aspirated,
cells were washed once with PBS-A (PBS without calcium and
magnesium, with 5.4 mM EDTA) and 10 μl of stock solution 5 mg/ml
MTT (resuspended in DMEM without FBS) was added to each well.
After incubation for 4 h at 37 °C, the MTT was aspirated and 150 μl of
acid–isopropanol solution (345 μl of hydrochloric acid (HCl) with
100 ml isopropanol) was added to each well and gently swirled for
10 min. The optical density was measured at 600 nm with a
microplate spectrophotometer (PowerWave 200, Bio-Tek Instru-
ments, Winoosky, VT).
DNA fragmentation
DNA from untreated or treated cells was extracted with lysis buffer
(50 mM KCl, 10 mM Tris pH 8.3, 2.5 mMMgCl2, 0.45% NP40 and 0.45%
Tween 20) containing Proteinase K (20 μg/μl), precipitatedwith isopro-
panol and fractioned on a 2% agarose gel. DNA was then visualized by
staining with ethidium bromide according to standard procedures.
Cell cycle analysis
Following stimulation, cells (2×106) were harvested, washed in
cold PBS1X/FBS 3% and centrifuged at 300 g for 5 min. Cells were
resuspended in 1 ml of cold PBS1X and 3 ml of cold absolute ethanol
was added while vortexing. Cells incubated for 2 h at 4 °C were then
washed and 500 μl of staining solution (25 μg/ml of propidium
iodide (Sigma Aldrich), 3.8 mM of sodium citrate (BioShop, Bur-
lington, Ont) and 0.5 μg/ml of RNase A (Sigma Aldrich)) was added.
After overnight incubation at 4 °C in the dark, the cells were run on a
BD FACSCalibur (BD Biosciences). FL2-A and FL2W detectors were
used for data acquisition and analyzed with the Cell Quest software
(BD Biosciences).
Viral production
Recombinant luciferase-encoding viruses (pHXB-luc) and the
infectious molecular clone (X4-tropic) pNL4-3 (Adachi et al., 1986)
were produced by calcium phosphate transfection in the 293 Tcells, as
9M. Boisvert et al. / Virology 380 (2008) 1–11described previously (Chen et al., 1994; Fortin et al., 1997). All virus
preparations underwent only one freeze–thaw cycle before initiation
of infection studies. Virus stocks were normalized for virion content
by using a double-antibody sandwich enzyme-linked immunosorbent
assay (ELISA) speciﬁc for the major core viral p24 protein (Roche).
HIV-1 infection assays
Caco-2 cells were inoculated with standardized amounts (50 ng of
p24) of the T-tropic luciferase reporter virus pHXB-luc. Cells were
lysed 48 h after virus inoculation and virus-encoded luciferase
activity was monitored by Lumat LB9507 Berthold luminometer
(Mander Scientiﬁc Company). Results shown are the means (±S.D.) of
triplicate samples and are expressed as fold induction relative to
basal luciferase activity in untreated/uninfected control cells. Also
Caco-2 cells were infected with wild-type NL4-3 to determine the
effect of PGJ2 on HIV-1 gene expression. Caco-2 cells were incubated
with 20 μM PGJ2 for 24 h before HIV-1 infection (100 ng of p24 per
2×105 cells). Infected cells were then treated with NaBut alone
(2 mM), PGJ2 alone (20 μM) or with a combination of both molecules
in quadruplicate for 72 h at 37 °C before determination of virus
production by measuring the p24 content.
Kinase assays
Following stimulation, Caco-2 cells (2×106) were resuspended in
500 μl of lysis buffer [50mMHEPES (pH7.4), 250mMNaCl,1% (v/v) NP-
40, 1 mM EDTA, 1 mM PMSF, 5 mM NaF, 20 μg/ml aprotinin, 20 μg /ml
leupeptin] for 30 min on ice. One μg of an IKKα/IKKβ cross-reactive
antibody (anti-IKKα/H744, Santa Cruz Biotechnology Inc., (Santa Cruz,
Ca)) was incubatedwith lysed-cells for 2 h at 4 °C on rotating platform.
Endogenous IKKs were immunoprecipitated with A/G plus agarose
beads (Santa Cruz Biotechnology) for 2 h at 4 °C, on rotating platform.
After extensive washes, immunoprecipitates were ﬁnally resuspended
in 20 μl of kinase reaction mix [10 mM HEPES (pH7,4), 1 mM MnCl2,
5mMMgCl2,12, 5mMglycerol 2-phosphate, 50 μMNa3VO4, 2mMNaF,
500 μM DTT, and 10 mM ATP] added along with 1 μg of puriﬁed IκBα
(1–317) (Santa Cruz Biotechnology) and 5 μCi of [γ-32P] ATP (Perkin
Elmer Las, Inc, Wookbridge, ON) and incubated for 1 h at 30 °C. SDS
loading buffer was added to the kinase reaction products that were
then boiled for 5 min at 95 °C, loaded on 10% SDS-Page gel and ran for
90min at 120V. The polyacrylamide gelwas then electrotransferred on
nitrocellulose membrane (90 min, 100 V), which was autoradio-
graphed overnight at −80 °C on high performance autoradiography
ﬁlms (Hyperﬁlm MP, Amersham Biosciences Piscataway, NJ). The
membrane was then probed with an IKK speciﬁc antibody (anti-IKKα/
H744, Santa Cruz Biotechnology) to evaluate the loading quantity of
kinase products. The band intensity was quantiﬁed using a gel
documentation system (Alpha Digidoc System 12.01).
Preparation of nuclear extracts
Caco-2 cells were ﬁrst either left untreated or were treated for
15 min at 37 °C with 20 μM PGJ2 with or without 2 mM sodium
butyrate at 37 °C. The incubation of Caco-2 cells with the various
stimulating agents was terminated by the addition of ice-cold PBS, and
nuclear extracts were prepared according to the microscale prepara-
tion protocol (Schreiber et al., 1989). In brief, sedimented cells were
resuspended in 400 μl of cold buffer A (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, and 0.2 mM phenylmethylsulfonyl
ﬂuoride (PMSF)). The cells were allowed to swell on ice for 15 min,
after which 25 μl of a 10% solution of Nonidet P-40 was added and the
tubes were vigorously vortexed for 10 s. The homogenate was
centrifuged for 30 s at 12,000 ×g. The supernatant fraction was dis-
carded, and the cell pellet was resuspended in 50 μl of cold buffer B
(20 mM HEPES–KOH, pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mMMgCl2, 0.2 mMEDTA, 0.5mMDTT, and 0.2mMPMSF) incubated on ice
for 15 min on a shaking platform. Cellular debris were removed by
centrifugation at 12,000 ×g for 2 min at 4 °C, and the supernatant
fractions were stored at −70 °C until used. Six micrograms of nuclear
extracts was used to perform an electrophoretic mobility shift assay
(EMSA). Protein content was determined by the commercial BCA
Protein Assay Reagent (Pierce, Rockfold, IL).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were incubated for 30 min at room temperature
in the binding buffer (100 mM HEPES [pH 7.9], 40% glycerol, 10%
Ficoll, 250 mM KCL, 10 mM dithiothreitol, 5 mM EDTA, 250 mM
NaCl, 2 μg poly [dI–dC], 10 μg nuclease-free bovine serum albumin
fraction V) containing 1 ng of 32P-5′-end-labeled double-stranded
(ds DNA) oligonucleotide. Double-stranded DNA (100 ng) was
labeled with [γ-32P]-ATP and T4 polynucleotide kinase in a kinase
buffer (New England Biolabs, Beverly, MA). This mixture was incu-
bated for 30 min at 37 °C and the reaction was stopped with 5 μl of
0.2 M EDTA. The labeled oligonucleotide was extracted with phenol/
chloroform and passed trough a G-50 spin column. The consensus
NF-κB (5′-AGTTGAGGGGACTTTCCCAGGC-3′) (purchased from Santa
Cruz Biotechnology Inc.) was used as a probe and/or competitor. The
NNRE-1 sequence of the HIV-1 LTR (−358 to −320) (5′-CCAGGGCCA-
GGGGTCAGATATCCACTGACCTTTGGATGG-3′) was purchased from
IDT (Coralville, IA). DNA–protein complexes were resolved from
free-labeled DNA by electrophoresis in native 4% (w/v) polyacryla-
mide gels. The gels were subsequently dried and autoradiographed on
a Kodak™ Biomax MR ﬁlm at −85 °C. Cold competition assays were
conducted by adding a 50-fold molar excess of unlabeled dsDNA
oligonucleotide simultaneously with the labeled probe. Supershift
assays were performed by preincubation of nuclear extracts with
either speciﬁc anti-p50 or anti-p65 or anti-PPAR-γ polyclonal anti-
bodies (Santa Cruz Biotechnology Inc.) in the presence of all the
components of the binding reaction described above for 20 min at
room temperature prior to the addition of the probe.
Statistical analysis
All results were calculated as the mean±SEM of independent
experiments. Statistics were analyzed using one-way ANOVA. P values
less than 0.05 were considered signiﬁcant.
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